Mar. 27, 2024 - Substantial amendments to the Investment Canada Act (ICA) were enacted on March 22, 2024, with the passing of Bill C-34, the National Security Review of Investments Modernization Act. These amendments, long in the works, will come into effect on a date to be fixed by Cabinet. It...
Announcement
Davies Scores Top Ranking in Global Competition Review 2020
For the 12th consecutive year, Global Competition Review has named Davies an “Elite” Canadian firm in its annual listing of the world’s top competition practices – the highest category awarded in the jurisdiction.
The guide commends our role in a “long list of global deals” over the past year, as well as our continued track record of success in competition litigation. A sampling of our recent notable work includes acting for Celgene Corp. in its proposed US$74-billion purchase by Bristol-Myers Squibb Co.; acting for Monsanto on its €57-billion sale to Bayer, Pfizer on its proposed deal with GlaxoSmithKline related to their consumer healthcare businesses; and the Liquor Control Board of Ontario in successfully defending a multi-billion dollar class action alleging a price-fixing conspiracy.
Compiled independently, the GCR 100 provides a qualitative analysis of the law firms doing the most important competition and antitrust work around the world.
Related
Mar. 13, 2024 - The Canadian government recently issued two policy statements (IDM Statements) affirming that it will enhance its scrutiny under the Investment Canada Act (ICA) of foreign investments in the Canadian Interactive Digital Media (IDM) sector. One of the statements sets out the...
